RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @DeepTech_VC: Our Portfolio Company @InSilicoMeds made an unprecedented #scientific breakthrough ! This is an AlphaGo moment for the wh…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @Karolien1231: @frankkumli @FrankPonsaert @Karolien1231 @dr_wardsam @B_Hf_T @numerikare @HealthBuzzBE @giovbriganti Real time data & de…
RT @Karolien1231: @frankkumli @FrankPonsaert @Karolien1231 @dr_wardsam @B_Hf_T @numerikare @HealthBuzzBE @giovbriganti Real time data & de…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @HartungIngo: A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1…
A new case study about deep learning in drug discovery @NatureBiotech: in 7 weeks to potent, cell active & lead-like DDR1 inhibitors: https://t.co/C3L4jUV3Aq. Caveat: Using AI for such a target is like using Google Maps for locating Times Square. But y
Drug discovery --> forward! Congrats @InSilicoMeds
@frankkumli @FrankPonsaert @Karolien1231 @dr_wardsam @B_Hf_T @numerikare @HealthBuzzBE @giovbriganti Real time data & deep learning will change the way we see basic/fondamental research. A realistic vision of the future in clinical research.
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @DK_Analytics: Deep Knowledge Ventures's Portfolio Company @InSilicoMeds made an unprecedented #scientific breakthrough ! This is an Al…
RT @DeepTech_VC: Our Portfolio Company @InSilicoMeds made an unprecedented #scientific breakthrough ! This is an AlphaGo moment for the wh…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
Deep Knowledge Ventures's Portfolio Company @InSilicoMeds made an unprecedented #scientific breakthrough ! This is an AlphaGo moment for the whole #Pharma #Industry. #pharmacy #ai #drugdiscovery
Our Portfolio Company @InSilicoMeds made an unprecedented #scientific breakthrough ! This is an AlphaGo moment for the whole #Pharma #Industry. #pharmacy #ai #drugdiscovery
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
Unglaublich: mit Hilfe von #KI pharmazeutischer Wirkstoff von der Idee bis zur Synthese und Validierung in vitro und in vivo in nur 46 Tagen! #drugdiscovery
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
How do you like this @elonmusk ? https://t.co/BgC9mcdUIj https://t.co/sPrhgXrfE2
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
21日か。selectivityはどうなんだろ。後で確認 https://t.co/Cu6IeRqSPI
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
Check out a new paper from @InSilicoMeds coauthored by our members @d_polykovskiy and @Max__Kuznetsov in @NatureBiotech on variational inference, tensor decompositions, and reinforcement learning for drug discovery paper: https://t.co/v69gMUWfln code: ht
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @pranavrajpurkar: Neat! "GENTRL [combines] reinforcement learning, variational inference, and tensor decompositions into a generative tw…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
RT @aubreydegrey: Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juven…
Insilico publishes GENTRL. They use GAN-RL technology to collaborate with the leading longevity companies including Juvenescence, LineageCell (was BioTime), Napa, Elevian, and many others. https://t.co/vYRUuCJdDg
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
Elon Musk vs some asian guy on AI 1:0
RT @biogerontology: From the author of @Deep__Medicine. A book all of us own and we were mentioned in the book. With GANs! The team is supe…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
RT @NatureBiotech: #Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZm…
#Deeplearning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/9hyDYFCm7f https://t.co/sNBZDZmPhU
🤯 using AI w drug discovery
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
Nice study employing generative models for compound design https://t.co/NLnQNyD2gb
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @biogerontology: Happy Labor Day, my friends! I hope that soon you will not need to be doing much labor. Let's work hard towards a very…
RT @pipetterinchief: Deep learning enables rapid identification of potent DDR1 kinase inhibitors | Nature Biotechnology #AI #drugdiscovery…
RT @biogerontology: Happy Labor Day, my friends! I hope that soon you will not need to be doing much labor. Let's work hard towards a very…
RT @biogerontology: From the author of @Deep__Medicine. A book all of us own and we were mentioned in the book. With GANs! The team is supe…
RT @AgingBio: #AI generation of drugs with further in vitro and in vivo validation https://t.co/OaaGXhSaZd Kudos to the team @InSilicoMeds…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @biogerontology: Happy Labor Day, my friends! I hope that soon you will not need to be doing much labor. Let's work hard towards a very…
Deep learning enables rapid identification of potent DDR1 kinase inhibitors | Nature Biotechnology #AI #drugdiscovery https://t.co/A9GEJ793DG
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @biogerontology: From the author of @Deep__Medicine. A book all of us own and we were mentioned in the book. With GANs! The team is supe…
RT @biogerontology: From the author of @Deep__Medicine. A book all of us own and we were mentioned in the book. With GANs! The team is supe…
From the author of @Deep__Medicine. A book all of us own and we were mentioned in the book. With GANs! The team is super excited, and ready to publish new stuff. We just need to wait until we license a few molecules. 🤖🙏
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @InSilicoMeds: Biggest News Today. Insilico Medicine's team made a breakthrough in AI for drug discovery last year. Today we are far ah…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
Deep learning enables rapid identification of potent DDR1 kinase inhibitors https://t.co/pw3M7aSmEM
Awesome ! https://t.co/nlBHyqCqL8
RT @ElementoLab: First ever demonstration that AI can generate entirely novel, synthesizable, active molecules against specific pharmacolog…
RT @ElementoLab: First ever demonstration that AI can generate entirely novel, synthesizable, active molecules against specific pharmacolog…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
@minouye271 There are more media reports than the original publication 🤦🏽♂️ Found it finally. Here, if anyone wants to read. https://t.co/VxcZwRqxnZ
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @ElementoLab: First ever demonstration that AI can generate entirely novel, synthesizable, active molecules against specific pharmacolog…
RT @EricTopol: There's been a lot of buzz about #AI for drug discovery. But I think this is the best case yet: All in 46 days! https://t.co…
RT @ElementoLab: First ever demonstration that AI can generate entirely novel, synthesizable, active molecules against specific pharmacolog…
Neat! "GENTRL [combines] reinforcement learning, variational inference, and tensor decompositions into a generative two-step machine learning algorithm". Curious why self-organizing maps were used as choice of reward function?